Temple filler FDA approval: verify the product, plane, and purpose
Temple filler is not approved as a category. FDA approval belongs to a named product, a defined indication, an age range, an injection plane, and its labeling; a March 2026 supplement added temple hollowing for one Restylane product, not every filler or every temple technique.
Temple filler is FDA approved only when the clinic means an exact approved product used for its labeled temple-hollowing indication, patient population, and tissue plane. In March 2026, FDA approved a Restylane Contour supplement for temple hollowing in patients over age 21; that decision does not approve every hyaluronic-acid filler, every temple injection, or “facial balancing” as a category.124
That product-level answer is more useful than asking whether an ingredient is approved. Hyaluronic acid describes a material family. The approval record identifies the finished device, its version, where and how it was studied, the labeling a patient should receive, and the risks that must be discussed.
Approval has five coordinates
An approval claim should survive five matching questions. If one coordinate changes, the clinic may be describing a different use.
| Coordinate | What to match | What does not transfer |
|---|---|---|
| Product | Exact proprietary name and manufacturer | Another filler with a similar ingredient or texture |
| Purpose | Correction of the label-defined temple hollowing indication | Cheek shaping, brow lifting, headache treatment, or generalized facial balancing |
| Patient | The labeled age and other selection criteria | Automatic suitability for every adult |
| Plane and technique | The anatomical plane and administration directions in the labeling | Any depth, volume, instrument, or injection map |
| Record | PMA number, supplement, patient labeling, and current status | A training slide, distributor page, or screenshot saying “FDA approved” |
The March 2026 record is a PMA supplement, meaning FDA reviewed a change to an already approved device’s indications or labeling. It is not a 510(k) clearance and not a new approval for the entire filler category.1 The distinction matters because an injector can truthfully say a product is FDA approved while still proposing a use that is outside that product’s labeling.
Start with the box and syringe, not the menu name
“Temple filler” is a service label. Before consent, the record should identify the sealed product, manufacturer, lot, expiration date, volume, and intended treatment area. Compare that product name with FDA’s approved-filler directory and the specific PMA page.13
Do not accept an ingredient-only answer such as “it is FDA-approved HA.” Different hyaluronic-acid fillers have different particle or gel properties, delivery systems, approved regions, age ranges, and patient labeling. Approval of one member does not migrate across the family.
That statement leaves room for an informed off-label discussion without disguising it. Off-label use is not automatically improper, but it is not the same as FDA approval for the proposed use. The clinic should describe the evidence, rationale, alternatives, uncertainties, and consent record rather than borrowing the product’s approval in another area.
Temple anatomy makes the plan more than a volume choice
The temple is a layered region near important vessels and nerves. A visible hollow can reflect bone contour, fat compartments, muscle, skin, age-related change, prior surgery, or weight change. The proposed plane and endpoint should follow that anatomy—not a standard syringe quantity.
Ask the injector to mark the target at rest and in motion and explain:
- which layer is being treated and why;
- whether a needle, cannula, or combination is planned;
- how asymmetry and nearby vascular anatomy affect the map;
- what endpoint ends the session before a pre-purchased amount is used; and
- how the plan changes if the tissue behaves differently than expected.
The answer should be specific without becoming a promise. “Deep” and “safe plane” are not complete anatomical descriptions, and an approved label does not remove risks created by anatomy, technique, patient factors, or a counterfeit or mishandled product.
Approval does not mean risk-free
FDA lists common filler effects such as bruising, redness, swelling, pain, tenderness, itching, and rash, along with less common but serious complications. Accidental injection into a blood vessel can cause tissue injury, vision abnormalities including blindness, or stroke.2 The approval record weighs evidence for a bounded use; it does not certify an injector, guarantee an outcome, or convert a clinic into an emergency-capable setting.
A temple consultation should therefore include the clinic’s prevention and response system. The useful questions are operational:
- Who recognizes and leads a suspected vascular event?
- What product-specific reversal or emergency supplies are immediately available?
- What symptoms trigger urgent ophthalmic or emergency escalation?
- Which receiving facility or specialist is contacted, and how?
- How are the product, lot, dose, plane, and event documented?
The vascular-occlusion planning guide explains the response record in more detail. A complication plan is not a prediction that harm will occur; it is evidence that the practice has converted a known risk into assigned actions.
“FDA approved injector” is the wrong credential
FDA regulates the filler device, not the injector’s professional title. A course certificate, manufacturer training, state license, board certification, and facility policy answer different questions. Verify the professional’s active license and ask about experience with the exact region, complication recognition, and longitudinal follow-up.
Photographs can show a style, but they do not prove approval status or safety. If a gallery informs the decision, look for standardized lighting, unedited views, consistent time points, and cases with similar anatomy. Ask whether other treatments, weight change, or image processing contributed.
Read the consent form for scope drift
The written plan should name the product and region before the syringe is opened. Watch for language that expands “temple hollowing” into broad upper-face sculpting without identifying each area and its status. If the plan includes cheeks, brows, forehead, hairline, or another region, each use needs its own anatomical rationale and product-status explanation.
The quote should separate consultation, product units or syringes, follow-up, management of asymmetry, and the practice’s complication and revision policies. FDA approval does not establish a standard amount or price. Paying by syringe also does not make using the entire syringe the clinical endpoint.
- Name the finished product Record the proprietary name, manufacturer, lot, expiration date, and planned amount—not just “HA filler.”
- Match the indication Open the current PMA supplement or FDA directory and compare area, purpose, age, and labeling with the proposed plan.
- Map the anatomy Ask what structure creates the hollow, which plane is targeted, and how the plan handles asymmetry and adjacent vessels.
- Verify the operator and response chain Check the license, regional experience, product handling, emergency supplies, escalation pathway, and follow-up ownership.
- Keep the record Retain the consent, product sticker or lot record, treatment map, dose, photographs, aftercare instructions, and contact route.
Verify the claim before treatment
Ask: “Which exact FDA record matches the product, temple indication, patient, and planned plane—and where does today’s plan differ from that label?” A precise answer supports informed consent. A category claim such as “all our fillers are FDA approved” does not.
Sources
- U.S. Food and Drug Administration. Restylane Contour PMA supplement P140029/S054. March 2026 approval record for the exact product, temple-hollowing indication, age range, and labeling supplement. Accessed .
- U.S. Food and Drug Administration. Dermal fillers (soft tissue fillers). FDA overview of product-specific approvals, common and serious risks, and unapproved uses. Accessed .
- U.S. Food and Drug Administration. FDA-approved dermal fillers. Current directory for checking a named filler and its approved indication rather than relying on an ingredient family. Accessed .
- U.S. Food and Drug Administration. Restylane Contour P140029/S054 Summary of Safety and Effectiveness Data. Approval evidence, exact indication, study population, contraindications, adverse events, and post-approval requirements. Accessed .